204 related articles for article (PubMed ID: 24300978)
1. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
Khatri A; Williams BW; Fisher J; Brundage RC; Gurvich VJ; Lis LG; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK; Kirstein MN
Br J Cancer; 2014 Jan; 110(2):304-12. PubMed ID: 24300978
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
[TBL] [Abstract][Full Text] [Related]
3. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
[TBL] [Abstract][Full Text] [Related]
4. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Mitra AK; Kirstein MN; Khatri A; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK
Pharmacogenomics; 2012 Jul; 13(9):1009-21. PubMed ID: 22838949
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion.
Alharbi AF; Kratzke RA; D'Cunha J; Maddaus MA; Sanghavi K; Kirstein MN
Cancer Chemother Pharmacol; 2019 Feb; 83(2):387-391. PubMed ID: 30542769
[TBL] [Abstract][Full Text] [Related]
6. Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
Peters GJ; Clavel M; Noordhuis P; Geyssen GJ; Laan AC; Guastalla J; Edzes HT; Vermorken JB
J Chemother; 2007 Apr; 19(2):212-21. PubMed ID: 17434832
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.
Sugiyama E; Kaniwa N; Kim SR; Kikura-Hanajiri R; Hasegawa R; Maekawa K; Saito Y; Ozawa S; Sawada J; Kamatani N; Furuse J; Ishii H; Yoshida T; Ueno H; Okusaka T; Saijo N
J Clin Oncol; 2007 Jan; 25(1):32-42. PubMed ID: 17194903
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion.
Freise KJ; Martín-Jiménez T
J Vet Pharmacol Ther; 2006 Apr; 29(2):147-52. PubMed ID: 16515669
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Maring JG; Wachters FM; Slijfer M; Maurer JM; Boezen HM; Uges DR; de Vries EG; Groen HJ
Eur J Clin Pharmacol; 2010 Jun; 66(6):611-7. PubMed ID: 20213492
[TBL] [Abstract][Full Text] [Related]
10. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates.
Kerr JZ; Berg SL; Dauser R; Nuchtern J; Egorin MJ; McGuffey L; Aleksic A; Blaney S
Cancer Chemother Pharmacol; 2001 May; 47(5):411-4. PubMed ID: 11391856
[TBL] [Abstract][Full Text] [Related]
11. Does saturable formation of gemcitabine triphosphate occur in patients?
Tham LS; Wang LZ; Soo RA; Lee HS; Lee SC; Goh BC; Holford NH
Cancer Chemother Pharmacol; 2008 Dec; 63(1):55-64. PubMed ID: 18305939
[TBL] [Abstract][Full Text] [Related]
12. [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients].
Ramón-López A; Escudero-Ortiz V; Duart-Duart MJ; Pérez-Ruixo JJ; Valenzuela B
Farm Hosp; 2012; 36(4):194-206. PubMed ID: 22078546
[TBL] [Abstract][Full Text] [Related]
13. Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.
Gusella M; Pasini F; Bolzonella C; Meneghetti S; Barile C; Bononi A; Toso S; Menon D; Crepaldi G; Modena Y; Stievano L; Padrini R
Br J Clin Pharmacol; 2011 Mar; 71(3):437-44. PubMed ID: 21284703
[TBL] [Abstract][Full Text] [Related]
14. Influence of infusion method on gemcitabine pharmacokinetics: a controlled randomized multicenter trial.
Simon N; Romano O; Michel P; Pinçon C; Vasseur M; Lemahieu N; Barthélémy C; Hebbar M; Décaudin B; Odou P
Cancer Chemother Pharmacol; 2015 Oct; 76(4):865-71. PubMed ID: 26193987
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
van Moorsel CJ; Kroep JR; Pinedo HM; Veerman G; Voorn DA; Postmus PE; Vermorken JB; van Groeningen CJ; van der Vijgh WJ; Peters GJ
Ann Oncol; 1999 Apr; 10(4):441-8. PubMed ID: 10370787
[TBL] [Abstract][Full Text] [Related]
16. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
Veltkamp SA; Jansen RS; Callies S; Pluim D; Visseren-Grul CM; Rosing H; Kloeker-Rhoades S; Andre VA; Beijnen JH; Slapak CA; Schellens JH
Clin Cancer Res; 2008 Jun; 14(11):3477-86. PubMed ID: 18519780
[TBL] [Abstract][Full Text] [Related]
17. Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach.
Serdjebi C; Gattacceca F; Seitz JF; Fein F; Gagnière J; François E; Abakar-Mahamat A; Deplanque G; Rachid M; Lacarelle B; Ciccolini J; Dahan L
Ther Drug Monit; 2017 Jun; 39(3):290-296. PubMed ID: 28346313
[TBL] [Abstract][Full Text] [Related]
18. Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.
Grunewald R; Abbruzzese JL; Tarassoff P; Plunkett W
Cancer Chemother Pharmacol; 1991; 27(4):258-62. PubMed ID: 1998982
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment.
Kiani A; Köhne CH; Franz T; Passauer J; Haufe T; Gross P; Ehninger G; Schleyer E
Cancer Chemother Pharmacol; 2003 Mar; 51(3):266-70. PubMed ID: 12655447
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate.
Jiang X; Galettis P; Links M; Mitchell PL; McLachlan AJ
Br J Clin Pharmacol; 2008 Mar; 65(3):326-33. PubMed ID: 17961191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
